Michael J. Fox Foundation: Target Validation Pilot Awards 2015

Target Validation Pilot awards support research on promising, novel, PD-relevant targets. These awards are well-suited to projects where hypothetical or experimental rationale for a target is compelling but limited, and study results can make the case for continuing (or discontinuing) a line of research.

Proposals should focus on filling key translational gaps in target validation including characterisation and expression studies of the target in human-derived tissues or target manipulation in a suitable preclinical model relevant to Parkinson’s disease.

Funding & Duration

US $100,000 (approx. AUD $127,600) for 1 year.


Applications may be submitted by:

  • U.S. and non-U.S. biotechnology/pharmaceutical companies or other for-profit entities, either publicly or privately held.
  • U.S. and non-U.S. entities, public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
  • Post-doctoral fellows are eligible to apply as Principal Investigator (PI) to the Target Validation Pilot Awards program only and must collaborate with an Administrative PI who directs the laboratory in which the fellow will conduct research. The Administrative PI will be responsible for assisting in providing all institutional documents required for the project and will be required to sign any award contract. Training or mentoring-only proposals will not be considered.

Related Schemes

Submission Requirements & Due Dates

  • 27 May 2015 – Pre-Proposals submitted directly to Sponsor
  • Copy of Pre-Proposal forwarded to the Research Branch ASAP.
  • 29 July 2015 – full applications (by invitation only) submitted to the Research Branch for internal review.

Grants Officer: Dr Don McMaster


Further Information

This entry was posted in Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding. Bookmark the permalink.

Comments are closed.